|
US4200750A
(en)
|
1977-01-07 |
1980-04-29 |
Westwood Pharmaceuticals Inc. |
4-Substituted imidazo [1,2-a]quinoxalines
|
|
US6069143A
(en)
|
1994-12-20 |
2000-05-30 |
Smithkline Beecham Corporation |
Fibrinogen receptor antagonists
|
|
WO2003062252A1
(en)
|
2002-01-18 |
2003-07-31 |
Merck & Co., Inc. |
Edg receptor agonists
|
|
CA2472680A1
(en)
|
2002-01-18 |
2003-07-31 |
Merck & Co., Inc. |
Selective s1p1/edg1 receptor agonists
|
|
WO2003062248A2
(en)
|
2002-01-18 |
2003-07-31 |
Merck & Co., Inc. |
N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
|
|
AU2003217764A1
(en)
|
2002-03-01 |
2003-09-16 |
Merck & Co., Inc. |
Aminoalkylphosphonates and related compounds as edg receptor agonists
|
|
JP2005533058A
(ja)
|
2002-06-17 |
2005-11-04 |
メルク エンド カムパニー インコーポレーテッド |
Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
|
|
CN1788008A
(zh)
*
|
2003-05-15 |
2006-06-14 |
麦克公司 |
作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
|
|
TW200505442A
(en)
|
2003-05-19 |
2005-02-16 |
Genomics Inst Of The Novartis Res Foundation |
Immunosuppressant compounds and compositions
|
|
AU2004277947A1
(en)
*
|
2003-10-01 |
2005-04-14 |
Merck & Co., Inc. |
3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
|
|
WO2005058848A1
(en)
|
2003-12-17 |
2005-06-30 |
Merck & Co., Inc. |
(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
|
|
TW200538433A
(en)
|
2004-02-24 |
2005-12-01 |
Irm Llc |
Immunosuppressant compounds and compositiions
|
|
AU2005299851B2
(en)
|
2004-10-22 |
2011-03-17 |
Merck Sharp & Dohme Corp. |
2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
|
|
RU2404178C2
(ru)
|
2005-03-23 |
2010-11-20 |
Актелион Фармасьютиклз Лтд |
Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
|
|
CA2605594A1
(en)
|
2005-04-22 |
2006-11-02 |
Daiichi Sankyo Company, Limited |
Heterocyclic compound
|
|
WO2006131336A1
(en)
|
2005-06-08 |
2006-12-14 |
Novartis Ag |
POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
|
|
CA2619101A1
(en)
|
2005-08-23 |
2007-03-01 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
WO2007088450A2
(en)
*
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagonist of the h-3 receptor
|
|
EP2010524A2
(en)
|
2006-03-21 |
2009-01-07 |
Epix Delaware, Inc. |
S1p receptor modulating compounds
|
|
MX2008012738A
(es)
|
2006-04-03 |
2009-02-06 |
Astellas Pharma Inc |
Heterocompuesto.
|
|
JP2009269819A
(ja)
|
2006-08-25 |
2009-11-19 |
Asahi Kasei Pharma Kk |
アミン化合物
|
|
MX2009002234A
(es)
|
2006-09-08 |
2009-03-16 |
Actelion Pharmaceuticals Ltd |
Derivados de piridin-3-il como agentes inmunomoduladores.
|
|
GB0625648D0
(en)
|
2006-12-21 |
2007-01-31 |
Glaxo Group Ltd |
Compounds
|
|
DK2125797T3
(da)
|
2007-03-16 |
2014-02-10 |
Actelion Pharmaceuticals Ltd |
Aminopyridinderivater som s1p1/edg1-receptoragonister
|
|
US8202865B2
(en)
|
2007-10-04 |
2012-06-19 |
Merck Serono Sa |
Oxadiazole derivatives
|
|
KR20100092473A
(ko)
|
2007-11-01 |
2010-08-20 |
액테리온 파마슈티칼 리미티드 |
신규한 피리미딘 유도체
|
|
GB0725105D0
(en)
|
2007-12-21 |
2008-01-30 |
Glaxo Group Ltd |
Compounds
|
|
US20090298894A1
(en)
*
|
2008-04-21 |
2009-12-03 |
Asahi Kasei Pharma Corporation |
Amino acid compounds
|
|
EP2376484B1
(en)
*
|
2008-12-18 |
2015-04-22 |
Merck Serono S.A. |
Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
|
|
EP2202232A1
(en)
*
|
2008-12-26 |
2010-06-30 |
Laboratorios Almirall, S.A. |
1,2,4-oxadiazole derivatives and their therapeutic use
|
|
EP2210890A1
(en)
*
|
2009-01-19 |
2010-07-28 |
Almirall, S.A. |
Oxadiazole derivatives as S1P1 receptor agonists
|
|
US8404672B2
(en)
|
2009-01-23 |
2013-03-26 |
Bristol-Meyers Squibb Company |
Substituted heterocyclic compounds
|
|
JP2012515787A
(ja)
*
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
|
|
ES2405054T3
(es)
*
|
2009-01-23 |
2013-05-30 |
Bristol-Myers Squibb Company |
Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
|
|
US8399451B2
(en)
*
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
EP2592071B1
(en)
|
2009-10-29 |
2019-09-18 |
Bristol-Myers Squibb Company |
Tricyclic heterocyclic compounds
|
|
JP5735634B2
(ja)
|
2010-04-23 |
2015-06-17 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
|
|
CN103124727B
(zh)
|
2010-07-20 |
2015-03-25 |
百时美施贵宝公司 |
取代的3-苯基-1,2,4-噁二唑化合物
|
|
JP5869579B2
(ja)
|
2010-09-24 |
2016-02-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
|